[go: up one dir, main page]

PL1885399T3 - Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania - Google Patents

Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania

Info

Publication number
PL1885399T3
PL1885399T3 PL06771453T PL06771453T PL1885399T3 PL 1885399 T3 PL1885399 T3 PL 1885399T3 PL 06771453 T PL06771453 T PL 06771453T PL 06771453 T PL06771453 T PL 06771453T PL 1885399 T3 PL1885399 T3 PL 1885399T3
Authority
PL
Poland
Prior art keywords
antibodies
methods
humanized anti
antigen
expression
Prior art date
Application number
PL06771453T
Other languages
English (en)
Inventor
Leonard G Presta
Lori Y O'connell
Svetlana O Doronina
Original Assignee
Seattle Genetics Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1885399(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc, Genentech Inc filed Critical Seattle Genetics Inc
Publication of PL1885399T3 publication Critical patent/PL1885399T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06771453T 2005-05-26 2006-05-26 Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania PL1885399T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68485305P 2005-05-26 2005-05-26
PCT/US2006/020688 WO2006128103A2 (en) 2005-05-26 2006-05-26 Humanized anti-cd40 antibodies and their methods of use
EP06771453A EP1885399B1 (en) 2005-05-26 2006-05-26 Humanized anti-cd40 antibodies and their methods of use

Publications (1)

Publication Number Publication Date
PL1885399T3 true PL1885399T3 (pl) 2011-04-29

Family

ID=37452957

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06771453T PL1885399T3 (pl) 2005-05-26 2006-05-26 Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania

Country Status (19)

Country Link
US (4) US8303955B2 (pl)
EP (1) EP1885399B1 (pl)
JP (1) JP5027804B2 (pl)
KR (1) KR100991010B1 (pl)
CN (1) CN101237882B (pl)
AT (1) ATE485057T1 (pl)
AU (1) AU2006249305B2 (pl)
BR (1) BRPI0610470A2 (pl)
CA (1) CA2609269C (pl)
CR (1) CR9562A (pl)
DE (1) DE602006017690D1 (pl)
EC (1) ECSP078026A (pl)
ES (1) ES2354865T3 (pl)
IL (1) IL187594A0 (pl)
MA (1) MA29595B1 (pl)
NO (1) NO341793B1 (pl)
PL (1) PL1885399T3 (pl)
RU (1) RU2407544C2 (pl)
WO (1) WO2006128103A2 (pl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
RU2407544C2 (ru) * 2005-05-26 2010-12-27 Сиэтл Дженетикс, Инк. Гуманизированные анти-cd40-антитела и способы их применения
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
WO2008091954A2 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
DK3138854T3 (da) 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
CA2754743C (en) 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
ES2605228T3 (es) 2009-04-18 2017-03-13 Genentech, Inc. Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40
US20130052194A1 (en) * 2009-12-16 2013-02-28 The Trustees Of The University Of Pennsylvania Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
SG183947A1 (en) * 2010-03-31 2012-10-30 Boehringer Ingelheim Int Anti-cd40 antibodies
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
EP2688592A4 (en) 2011-03-25 2015-07-22 Baylor Res Inst Compositions and methods for immunization against the hepatitis C virus
EP2702078B1 (en) 2011-04-29 2018-11-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2851667A1 (en) * 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
MX375800B (es) 2014-04-30 2025-03-06 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpos humanizados contra cd269 (bcma).
KR102443258B1 (ko) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
SI3212230T1 (sl) 2014-10-29 2021-08-31 Seagen Inc. Doziranje in dajanje ne-fukoziliranih protiteles proti-CD40
US10864268B2 (en) * 2014-11-18 2020-12-15 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3344655B1 (en) * 2015-09-01 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of lupus nephritis
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
MA43053A (fr) * 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
WO2017062653A2 (en) * 2015-10-08 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Blockade of tim-1 for treating graft-versus-host disease
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
KR102587941B1 (ko) 2016-08-12 2023-10-11 얀센 바이오테크 인코포레이티드 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
US11186626B2 (en) 2016-10-11 2021-11-30 Integrated Biotherapeutics, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
US10828375B2 (en) * 2016-11-07 2020-11-10 Seattle Genetics, Inc. Distribution of engineered-cysteine caps
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
EP3606956B1 (en) * 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
JP7257971B6 (ja) 2017-06-01 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
BR112020006443A2 (pt) 2017-11-01 2020-09-29 F. Hoffmann-La Roche Ag anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
EP3861026A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising anti-fap clone 212
EP3861025A1 (en) * 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
MX2021005823A (es) 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo.
CN112839961B (zh) 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TWI851885B (zh) * 2020-03-30 2024-08-11 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combination therapy
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
TW202314247A (zh) 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20250009877A1 (en) 2021-07-30 2025-01-09 Seagen Inc. Treatment for cancer
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
ATE267607T1 (de) * 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6558671B1 (en) 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP1616579B1 (en) * 1998-05-23 2009-07-22 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU2001250814B2 (en) 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
BR0116680A (pt) * 2000-12-14 2005-04-05 Genentech Inc Linhagem de e. coli e método de produção de um polipeptìdeo
US7657380B2 (en) * 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
RU2407544C2 (ru) * 2005-05-26 2010-12-27 Сиэтл Дженетикс, Инк. Гуманизированные анти-cd40-антитела и способы их применения

Also Published As

Publication number Publication date
CN101237882B (zh) 2012-08-15
ATE485057T1 (de) 2010-11-15
EP1885399A4 (en) 2009-04-22
WO2006128103A2 (en) 2006-11-30
KR20080030958A (ko) 2008-04-07
EP1885399B1 (en) 2010-10-20
EP1885399A2 (en) 2008-02-13
WO2006128103A3 (en) 2007-01-18
US20090181015A1 (en) 2009-07-16
CA2609269A1 (en) 2006-11-30
AU2006249305A1 (en) 2006-11-30
US8492531B2 (en) 2013-07-23
RU2007148932A (ru) 2009-07-10
NO20076404L (no) 2008-02-13
JP5027804B2 (ja) 2012-09-19
NO341793B1 (no) 2018-01-22
ES2354865T3 (es) 2011-03-18
BRPI0610470A2 (pt) 2010-06-22
KR100991010B1 (ko) 2010-10-29
US20130315900A1 (en) 2013-11-28
IL187594A0 (en) 2008-03-20
CN101237882A (zh) 2008-08-06
US20140193405A1 (en) 2014-07-10
JP2008541733A (ja) 2008-11-27
CR9562A (es) 2008-03-06
US20130023047A1 (en) 2013-01-24
DE602006017690D1 (de) 2010-12-02
US8303955B2 (en) 2012-11-06
ECSP078026A (es) 2008-03-26
AU2006249305B2 (en) 2012-10-18
MA29595B1 (fr) 2008-07-01
RU2407544C2 (ru) 2010-12-27
CA2609269C (en) 2014-08-05

Similar Documents

Publication Publication Date Title
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
TN2012000555A1 (en) Antibodies to human gdf8
NZ572756A (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
UA92504C2 (en) Anti-myostatin monoclonal antibody
IL188591A0 (en) Methods of treating autoimmune disease using humanized anti-cd16a antibodies
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
WO2007101021A3 (en) Humanized anti-ghrelin antibodies
UA112521C2 (uk) Антитіло проти gdf8 людини